Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1701-1708

  Gosselin, Antoine ^a   Pashos, Chris L ^b   Harley, Carolyn ^c   Mark, Tami L ^d   McKenzie, R Scott ^e  

^a GROUPE D ANALYSE   (Canada)

^b ABT ASSOCIATES   (United States)

^c Ingenix Inc   (United States)

^d MEDSTAT GROUP   (United States)

^e Ortho Biotech Products LP   (United States)

Author keywords

anemia; darbepoetin alfa; dosing; epoetin alfa; hemoglobin; medical resource utilization

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER CENTER; CANCER PATIENT; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; TREATMENT DURATION;

DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OFFICE VISITS;

EID: 33845261584     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.009     Document Type: Article

References (31)

1. [published correction appears in J Natl Cancer Inst. 2000;92:497]. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 917 (1999) 1616-1634
2. Harrison L., Shasha D., Shiaova L., et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 28 Suppl 8 (2001) 54-59
3. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 25 Suppl 7 (1998) 43-46
4. Sobrero A., Puglisi F., Guglielmi A., et al. Fatigue: A main component of anemia symptomatology. Semin Oncol 28 Suppl 8 (2001) 15-18
5. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor forsurvival in patients with cancer: A systemic, quantitative review. Cancer 91 (2001) 2214-2221
6. Procrit (epoetin alfa) [package insert] (2005), Ortho Biotech Products, Raritan, NJ
7. Aranesp (darbepoetin alfa) [package insert] (2005), Amgen Inc, Thousand Oaks, Calif.
8. Portenoy R.K., and Itri L.M. Cancer-related fatigue: Guidelines for evaluation and managment. Oncologist 4 (1999) 1-10
9. Gabrilove J.L., Cleeland C.S., Livingston R.B., et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19 (2001) 2875-2882
10. Steensma D.P., Molina R., Sloan J.A., et al. Phase III study of two different dosing schedules of erythropoietin in anemic patientswith cancer. J Clin Oncol 24 (2006) 1079-1089
11. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial ofdarbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
12. Hesketh P.J., Arena F., Patel D., et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in pa tients with anemia who have nonmyeloid malignancies. Cancer 100 (2004) 859-868
13. Kotasek D., Steger G., Faught W., et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39 (2003) 2026-2034
14. Patton J., Kuzur M., Liggett W., et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9 (2004) 90-96
15. Schwartzberg L.S., Yee L.K., Senecal F.M., et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 9 (2004) 696-707
16. Smith Jr. R.E., Tchekmedyian N.S., Chan D., et al. A dose- and schedulefinding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88 (2003) 1851-1858
17. Vadhan-Raj S., Mirtsching B., Charu V., et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 1 (2003) 131-138
18. Canon J.L., Vansteenkiste J., Bodoky G., et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 98 (2006) 273-284
19. Glaspy J., Vadhan-Raj S., Patel R., et al., 20030125 Study Group. Randomized comparison of every2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24 (2006) 2290-2297
20. Mark T.L., McKenzie R.S., Fastenau J., and Piech C.T. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 21 (2005) 1347-1354
21. Las Vegas, Nevada. Harley C., Muser E., Nelson M., et al. Epoetin alfa and darbepoetin alfa utilization patterns among cancer patients. Poster presented at: 40th American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting (December 4-8, 2005)
22. Atlanta, Georgia. Gosselin A., Lefebvre P., Duh M.S., et al. Dosing patterns and transfusion use in cancer patients treated with erythropoietic agents: Results from an observational study of over 8000 patients. Poster presented at: 47th Annual Meeting of the American Society of Hematology (ASH) (December 10-13, 2005)
23. Las Vegas, Nevada. Memisoglu A., Peake C., Kshirsagar R.V., et al. Hematologic outcomes and costs in epoetin alfa (FPO) and darbepoetin alfa (DARB) treated cancer patients: Results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) Registry. Poster presented at: 40th American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting (December 4-8, 2005)
24. Grad O., Davis J., Vichare R., et al. Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) [abstract]. Support Care Cancer 12 (2004) 419
25. Available at:. United States Department of Health and Human Services, Centers for Medicaid and Medicare Services. Health Insurance Portability and Accountability Act of 1996. Accessed September 18 (2006). http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAAlawdetail.pdf.
26. Cremieux P.Y., Fastenau J.M., Kosicki G., et al. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J Manag Care Pharm 10 (2004) 531-537
27. Beveridge R.A., Rifkin R.M., Moleski R.J., et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 237 (2003) 101S-109S
28. Fortner B., Tauer K., Zhu L., et al. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: A national survey. Commun Oncol 17 (2004) 211-217
29. (15S Part 1 of II). Bolge S.C., Fastenau J.M., Howell J.B., et al. Final results from a choice based conjoint study assessing pa tient preferences for selected features of erythropoietic agents. [abstract]. J Clin Oncol 23 (2005) 8248
30. Herrington J.D., Davidson S.L., Tomita D.K., et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy induced anemia. Am J Health Syst Pharm 62 (2005) 754-762
31. Schwartzberg L., Shiffman R., Tomita D., et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 25 (2003) 2781-2796